Monopar Therapeutics (NASDAQ:MNPR) Director Kim Tsuchimoto Sells 4,090 Shares of Stock

Monopar Therapeutics Inc. (NASDAQ:MNPR) Director Kim Tsuchimoto sold 4,090 shares of the company’s stock in a transaction on Wednesday, August 26th. The shares were sold at an average price of $111.39, for a total transaction of $455,585.10. Following the sale, the director owned 7,396 shares of the company’s stock, valued at $823,840.44. The trade was a 35.61% decrease in their position. The sale was disclosed in a legal filing with the SEC, which is accessible through the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan.

Monopar Therapeutics Stock Up 0.2%

MNPR stock opened at $113.94 on Friday. The business’s fifty day moving average is $105.56 and its 200-day moving average is $74.74. The company has a market cap of $764.54 million, a P/E ratio of -52.51 and a beta of 1.47. Monopar Therapeutics Inc. has a twelve month low of $32.77 and a twelve month high of $124.82.

Monopar Therapeutics (NASDAQ:MNPR) last announced its quarterly earnings data on Wednesday, August 12th. The company reported ($0.62) EPS for the quarter, topping analysts’ consensus estimates of ($0.64) by $0.02. Research analysts anticipate that Monopar Therapeutics Inc. will post -2.94 earnings per share for the current fiscal year.

Hedge Funds Weigh In On Monopar Therapeutics

Large investors have recently bought and sold shares of the company. Janus Henderson Group PLC raised its holdings in shares of Monopar Therapeutics by 2.3% in the fourth quarter. Janus Henderson Group PLC now owns 1,317,410 shares of the company’s stock valued at $85,908,000 after purchasing an additional 30,042 shares during the last quarter. RA Capital Management L.P. grew its position in Monopar Therapeutics by 30.5% in the fourth quarter. RA Capital Management L.P. now owns 667,207 shares of the company’s stock valued at $43,569,000 after purchasing an additional 156,000 shares in the last quarter. Siren L.L.C. increased its stake in Monopar Therapeutics by 27.2% in the 1st quarter. Siren L.L.C. now owns 270,118 shares of the company’s stock valued at $14,800,000 after buying an additional 57,820 shares during the last quarter. ADAR1 Capital Management LLC increased its stake in Monopar Therapeutics by 13.0% in the 1st quarter. ADAR1 Capital Management LLC now owns 264,278 shares of the company’s stock valued at $14,480,000 after buying an additional 30,370 shares during the last quarter. Finally, Wellington Management Group LLP bought a new stake in Monopar Therapeutics during the 3rd quarter worth about $18,904,000. Institutional investors and hedge funds own 1.83% of the company’s stock.

Analyst Upgrades and Downgrades

A number of analysts have recently commented on the company. Cantor Fitzgerald cut Monopar Therapeutics from an “overweight” rating to a “neutral” rating and upped their price target for the company from $109.00 to $119.00 in a research note on Thursday, August 13th. Piper Sandler set a $105.00 price objective on shares of Monopar Therapeutics in a research note on Tuesday, June 2nd. Wall Street Zen cut shares of Monopar Therapeutics from a “hold” rating to a “sell” rating in a report on Sunday, August 16th. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Monopar Therapeutics in a research note on Friday, July 17th. Finally, UBS Group set a $125.00 target price on shares of Monopar Therapeutics in a report on Thursday, July 23rd. Two investment analysts have rated the stock with a Strong Buy rating, nine have issued a Buy rating, two have issued a Hold rating and one has assigned a Sell rating to the company. Based on data from MarketBeat, the company has an average rating of “Moderate Buy” and a consensus target price of $118.67.

About Monopar Therapeutics

Monopar Therapeutics, Inc is a clinical-stage biotechnology company focused on the development of novel targeted radiotherapeutics and next-generation antibody-drug conjugates for the treatment of cancer. The company’s core technology leverages a pretargeted radioimmunotherapy (PRIT) platform designed to deliver potent radioisotopes to tumor cells while minimizing exposure to healthy tissues. By combining small-molecule binding agents with specialized radioisotopes, Monopar aims to improve the therapeutic index of radiation-based cancer therapies.

The company’s pipeline includes multiple oncology candidates in various stages of preclinical and early clinical development.